Spitz Jared, Patel Jaideep, Agarwala Anandita, Sharma Garima, Mehta Anurag, Natarajan Pradeep, Nasir Khurram, Morris Pamela, Blumenthal Roger S, Shapiro Michael D
Inova Schar Heart and Vascular, Inova Health System, Falls Church, Virginia, USA.
Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins Hospital, Baltimore, Maryland, USA.
JACC Adv. 2025 Jun;4(6 Pt 2):101823. doi: 10.1016/j.jacadv.2025.101823.
The role of low-density lipoprotein-cholesterol in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD) is well established. Lipid management remains the cornerstone of addressing ASCVD. In addition to statin therapy, there is a large and growing number of nonstatin therapies available to manage elevated cholesterol levels. This expert panel seeks to review current international recommendations regarding lipid management. In addition, complex yet commonly encountered lipid-management cases are provided. Guidance on applying guideline-based recommendations as well as newer evidence to the evaluation and management of ASCVD-risk lipid management is then provided.
低密度脂蛋白胆固醇在动脉粥样硬化性心血管疾病(ASCVD)发病机制中的作用已得到充分证实。脂质管理仍然是应对ASCVD的基石。除了他汀类药物治疗外,还有大量且不断增加的非他汀类疗法可用于控制升高的胆固醇水平。该专家小组旨在回顾当前关于脂质管理的国际建议。此外,还提供了复杂但常见的脂质管理病例。随后提供了关于将基于指南的建议以及新证据应用于ASCVD风险脂质管理评估和管理的指导。